IQVIA (NYSE:IQV) Rating Increased to Buy at StockNews.com

StockNews.com upgraded shares of IQVIA (NYSE:IQV) from a hold rating to a buy rating in a research report sent to investors on Wednesday morning.

A number of other research firms also recently issued reports on IQV. Truist Financial dropped their price target on IQVIA from $286.00 to $265.00 and set a “buy” rating on the stock in a research report on Monday, November 4th. Robert W. Baird reduced their price target on shares of IQVIA from $256.00 to $223.00 and set a “neutral” rating for the company in a report on Friday, November 1st. TD Cowen dropped their price objective on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Jefferies Financial Group downgraded shares of IQVIA from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $266.00 to $242.00 in a research note on Wednesday, July 24th. Finally, JPMorgan Chase & Co. dropped their target price on IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 5th. Four research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $256.50.

IQVIA Stock Up 2.1 %

Shares of NYSE:IQV opened at $201.82 on Wednesday. The business’s 50 day moving average is $222.67 and its 200 day moving average is $227.18. The stock has a market cap of $36.63 billion, a P/E ratio of 26.49, a price-to-earnings-growth ratio of 2.03 and a beta of 1.51. IQVIA has a 52-week low of $187.62 and a 52-week high of $261.73. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76.

Insider Activity

In other news, insider Eric Sherbet sold 1,300 shares of IQVIA stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the sale, the insider now directly owns 19,536 shares in the company, valued at approximately $4,812,302.88. The trade was a 6.24 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 1.60% of the company’s stock.

Institutional Trading of IQVIA

A number of institutional investors and hedge funds have recently added to or reduced their stakes in IQV. Canada Pension Plan Investment Board raised its stake in shares of IQVIA by 6.6% in the second quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company’s stock worth $719,634,000 after purchasing an additional 211,653 shares during the last quarter. Lazard Asset Management LLC raised its position in IQVIA by 0.9% during the 1st quarter. Lazard Asset Management LLC now owns 3,263,944 shares of the medical research company’s stock worth $825,416,000 after buying an additional 30,014 shares during the last quarter. Farallon Capital Management LLC lifted its stake in IQVIA by 3.1% during the 2nd quarter. Farallon Capital Management LLC now owns 2,923,032 shares of the medical research company’s stock valued at $618,046,000 after acquiring an additional 86,870 shares during the period. FMR LLC boosted its holdings in shares of IQVIA by 38.7% in the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock valued at $684,213,000 after acquiring an additional 804,963 shares during the last quarter. Finally, Capital Research Global Investors increased its stake in shares of IQVIA by 7.2% in the first quarter. Capital Research Global Investors now owns 2,138,802 shares of the medical research company’s stock worth $540,882,000 after acquiring an additional 143,533 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.